ACL's play for pathology company Healius faces pushback from Australian regulator
MLex Summary: Australian Clinical Labs’ bid to acquire human-pathology peer Healius is facing regulatory headwinds, with the country’s competition regulator saying that the deal raises “significant preliminary competition concerns.” In a...To view the full article, register now.
Already a subscriber? Click here to view full article